Evelo Biosciences reports Q3 EPS (28c), consensus (33c)

As of September 30, cash and cash equivalents were $69.1M, as compared to cash and cash equivalents of $68.4M as of December 31, 2021. "We are on-track to deliver on three Phase 2 clinical milestones throughout 2023: first, early in the first quarter of 2023, data from the first three cohorts in the Phase 2 trial of EDP1815 in atopic dermatitis; second, in the second quarter of 2023, data from the fourth cohort – the faster release capsule – in the Phase 2 trial of EDP1815 in atopic dermatitis; and third, in the second half of 2023, data from patients in the Phase 2 trial of EDP2939, our first extracellular vesicle (EV) product candidate, in psoriasis" said Simba Gill, CEO of Evelo.